Innovative Test Accurately Detects Brain Cancers Using Cerebrospinal Fluid
A novel multi-analyte test developed by Johns Hopkins researchers can accurately diagnose brain cancers from cerebrospinal fluid, offering a less invasive and highly reliable diagnostic tool.
A groundbreaking multi-analyte testing method developed by researchers at Johns Hopkins University offers a highly precise way to identify brain cancers from small samples of cerebrospinal fluid (CSF). This innovative approach provides a powerful new tool to aid in clinical decision-making, potentially reducing the need for invasive procedures.
Published in the journal Cancer Discovery on August 25, 2025, the study demonstrates that combining multiple biological markers—including tumor-derived DNA, chromosomal abnormalities, mutations, and immune cell signatures—improves diagnostic accuracy over single-marker tests. The researchers analyzed 206 CSF samples from patients diagnosed with various central nervous system cancers, such as gliomas, medulloblastomas, metastases, and lymphomas. Their test, known as CSF-BAM, measures relevant genetic alterations and immune receptor sequences.
Results showed that the test could detect brain cancers with over 80% sensitivity and achieved 100% specificity, meaning it correctly identified all cancer-free individuals and had no false positives in the validation phase. Additionally, the assay was capable of differentiating immune cell populations in CSF, offering insights into tumor behavior and immune environment, which can be invaluable in treatment planning.
This tool could prove especially useful in cases where traditional imaging or cytology results are inconclusive, or when surgical biopsy presents significant risks. By enabling more accurate and less invasive diagnosis, CSF-BAM supports personalized treatment strategies and could lead to earlier detection of brain tumors.
Senior author Dr. Chetan Bettegowda emphasized the importance of evaluating multiple analytes concurrently to improve diagnostic confidence and gain a better understanding of tumor immune responses. This multi-faceted approach marks a significant advancement in neuro-oncology diagnostics.
Source: Medical Xpress by Johns Hopkins University
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Michigan's Medicaid Work Requirement System: Lessons and Warnings for Other States
Michigan's Medicaid work requirement system faced legal challenges and implementation hurdles, offering critical lessons for other states considering similar policies amid ongoing debates over healthcare coverage and costs.
The Future of Disease Prevention: Building Universal Vaccines for Global Immunity
Scientists are making strides toward developing universal vaccines that offer broad protection against multiple virus strains, promising to revolutionize global disease prevention and reduce healthcare burdens.
Research Links Head Injuries to Increased Risk of Malignant Brain Tumors
New research reveals a potential higher risk of malignant brain tumors in individuals with a history of traumatic brain injury, emphasizing the importance of long-term monitoring for at-risk patients.
Experts Call for Enhanced Blood Clot Prevention Strategies After Leg Artery Procedures in High-Risk Patients
European experts recommend stronger blood clot prevention measures for high-risk CLTI patients after revascularization procedures to reduce limb and cardiovascular complications.